Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending June 2014. The report details a specific corporate action regarding share repurchases executed on June 4, 2014, pursuant to shareholder authority granted at the Annual General Meeting on May 7, 2014.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 822,500 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,588.50 pence per share; lowest price paid was 1,575.50 pence per share.
- Treasury Holdings (Settled): 495,893,414 shares (9.27% of total issued share capital).
- Treasury Holdings (Including Unsettled): 497,973,914 shares (10.26% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,854,817,988 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 822,500 shares for treasury. Consequently, the percentage of shares held in treasury increased to 10.26% of total voting rights when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Conduct Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in treasury (495,893,414 settled) against the company's latest capitalization table.
- Confirm the calculation of total voting rights (10.26% held in treasury including unsettled shares) for disclosure threshold assessments.
- Review the price paid per share (1,575.50 to 1,588.50 pence) against market prices on June 4, 2014.
- Note that this filing does not contain operational or financial performance data; refer to Form 20-F for comprehensive financial statements.